1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Dabrafenib (BRAF Inhibitor): new trials by email Literature Review of Dabrafenib (BRAF Inhibitor) trials Research Report on Dabrafenib (BRAF Inhibitor)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor) - Melanoma (Skin), Melanoma Stage IIIb-IVM1a | Phase 2 | Withdrawn | TriHealth Inc. | 2019-06-24 | 2020-10-19 |
Melanoma (1) · Skin Neoplasms (1)
TriHealth Inc. (1)
United States (1)